晚期肺腺癌EGFR-TKIs对后续培美曲赛化疗的影响
晚期肺腺癌EGFR-TKIs对后续培美曲赛化疗的影响
About this item
Full title
Author / Creator
Publisher
上海交通大学附属胸科医院肺内科,上海,200030
Journal title
Language
Chinese
Formats
Publication information
Publisher
上海交通大学附属胸科医院肺内科,上海,200030
Subjects
More information
Scope and Contents
Contents
背景与目的培美曲赛和表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs）对于有EGFR基因突变的非小细胞肺癌（non-small cell lung cancer,NSCLC）患者能获得比野生型更好的疗效。本研究旨在通过临床观察肺腺癌患者EGFR-TKIs进展后后续培美曲赛化疗的疗效和毒副反应,分析EGFR-TKIs对后续培美曲赛化疗的影响。方法收集III期和IV期肺腺癌患者,根据有无EGFR-TKIs治疗史分为靶向治疗组和非靶向治疗组。所有患者接受培美曲赛（500 mg/m2）,均为二线及二线以上治疗。按照RECIST（Response Evaluation Crit...
Alternative Titles
Full title
晚期肺腺癌EGFR-TKIs对后续培美曲赛化疗的影响
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_wanfang_journals_zgfazz201205008
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_wanfang_journals_zgfazz201205008
Other Identifiers
ISSN
1009-3419
E-ISSN
1999-6187
DOI
10.3779/j.issn.1009-3419.2012.05.08
